Intriguingly, DLL1 expression levels in ERα− subtypes of breast cancer, including TNBC/basal and HER2+, do not correlate with prognosis, highlighting a potential subtype-specific function for DLL1 in ERα+ breast cancer. This evidence concerns the gene DLL1 and breast carcinoma.